Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model

S. Siebeneicher, S. Reuter, A. Wangorsch, M. Krause, K. Foetisch, A. Heinz, S. Naito, A. Reuter, C. Taube, S. Vieths, S. Scheurer, M. Toda

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background Due to reduced allergic potency, hypoallergenic variants have been suggested as safer and potentially more efficacious alternative to the corresponding wild-type allergens in allergen-specific immunotherapy. Here, we aimed at investigating the efficacy of recombinant Bet v 1B2, a hypoallergenic folding variant of Bet v 1, in epicutaneous immunotherapy to suppress asthmatic features using a murine model of birch pollen allergy. Methods and Results Before, or after sensitization with rBet v 1 plus ALUMW and intranasal challenges with birch pollen extract, BALB/c mice received epicutaneous immunization (EPI) with rBet v 1, or rBet v 1B2 on their depilated back. Prophylactic EPI with rBet v 1B2, but not with rBet v 1, suppressed serum levels of Bet v 1-specific IgE antibodies and reduced the number of eosinophils and the concentrations of Th2 cytokines in bronchoalveolar lavage. In an established allergic condition, serum levels of Bet v 1-specific IgE antibodies were similar between PBS-treated control mice and EPI-treated mice. However, therapeutic EPI with rBet v 1B2, but not with rBet v 1, significantly suppressed the development of airway inflammation and lung function impairment. Conclusion This study is the first to show the effect of therapeutic EPI with a recombinant form of a hypoallergenic folding variant on the suppression of asthmatic features. Our results suggest that rBet v 1B2 along with its reduced IgE-binding capacity could be a preferred therapeutic allergen than wild-type rBet v 1 in epicutaneous immunotherapy of birch pollen-induced allergic asthma, in particular due to a lower risk of allergic side effect.

Original languageEnglish
Pages (from-to)1559-1568
Number of pages10
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume70
Issue number12
DOIs
Publication statusPublished - 2015 Dec 1
Externally publishedYes

Keywords

  • birch pollen allergy
  • epicutaneous immunization
  • hypoallergen

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model'. Together they form a unique fingerprint.

  • Cite this

    Siebeneicher, S., Reuter, S., Wangorsch, A., Krause, M., Foetisch, K., Heinz, A., Naito, S., Reuter, A., Taube, C., Vieths, S., Scheurer, S., & Toda, M. (2015). Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model. Allergy: European Journal of Allergy and Clinical Immunology, 70(12), 1559-1568. https://doi.org/10.1111/all.12732